CIK 0001388320 · Non-accelerated filer<br>Smaller reporting company
Actinium Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ATNM
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880378336
- Phone
- (646) 677-3870
- Business address
- 100 PARK AVE., 23RD FLOOR, NEW YORK, NY, 10017
- Former names
- Cactus Ventures, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-03-14 | DAVE KAUSHIK J CEO and Interim CFO | Grant or award · Options to purchase common stock | +250,000 | $1.39 | $348K | 250,000 |
| 2017-03-14 | SETH SANDESH Executive Chairman | Other acquisition · Warrant to purchase common stock | +64,746 | $0.78 | $51K | 64,746 |
| 2017-03-14 | SETH SANDESH Executive Chairman | Other acquisition · Warrant to purchase common stock | +99,619 | $0.78 | $78K | 99.62 |
| 2017-03-14 | SETH SANDESH Executive Chairman | Other disposition · Warrant to purchase common stock | −57,212 | $2.34 | $134K | 0 |
| 2017-03-14 | SETH SANDESH Executive Chairman | Grant or award · Warrant to purchase common stock | +57,212 | $2.34 | $134K | 57,212 |
| 2017-03-14 | SETH SANDESH Executive Chairman | Grant or award · Options to purchase common stock | +750,000 | $1.39 | $1.0M | 750,000 |
| 2017-03-14 | TRAVERSA SERGIO Director | Grant or award · Options to purchase common stock | +75,000 | $1.39 | $104K | 75,000 |
| 2017-03-14 | Nicholson, C. David Director | Grant or award · Options to purchase common stock | +75,000 | $1.39 | $104K | 75,000 |
| 2017-03-14 | Steinhart Richard I Director | Grant or award · Options to purchase common stock | +75,000 | $1.39 | $104K | 75,000 |
| 2017-03-14 | CICIC DRAGAN Chief Technology Officer | Grant or award · Options to purchase common stock | +75,000 | $1.39 | $104K | 75,000 |
| 2016-12-30 | SETH SANDESH Executive Chairman | Purchase | +5,000 | $0.88 | $4K | 35,000 |
| 2016-12-12 | SETH SANDESH Executive Chairman | Purchase | +5,000 | $0.98 | $5K | 30,000 |
| 2016-08-31 | Memorial Sloan-Kettering Cancer Center 10% owner | Sale | −25,188 | $1.80 | $45K | 4,821,226 |
| 2016-08-31 | Memorial Sloan-Kettering Cancer Center 10% owner | Sale | −6,400 | $1.81 | $12K | 4,814,826 |
| 2016-08-31 | Memorial Sloan-Kettering Cancer Center 10% owner | Sale | −200 | $1.82 | $363 | 4,814,626 |
| 2016-08-31 | Memorial Sloan-Kettering Cancer Center 10% owner | Sale | −25,100 | $1.82 | $46K | 4,789,526 |
| 2016-08-31 | Memorial Sloan-Kettering Cancer Center 10% owner | Sale | −800 | $1.83 | $1K | 4,788,726 |
| 2016-08-31 | Memorial Sloan-Kettering Cancer Center 10% owner | Sale | −15,000 | $1.84 | $28K | 4,773,726 |
| 2016-08-31 | Memorial Sloan-Kettering Cancer Center 10% owner | Sale | −40,200 | $1.85 | $74K | 4,733,526 |
| 2016-08-31 | Memorial Sloan-Kettering Cancer Center 10% owner | Sale | −9,800 | $1.86 | $18K | 4,723,726 |
Page 8 of 16 · 316 trades